New hope for hard-to-treat blood cancers? AC676 enters human testing.
Disease control
Recruiting now
This early-stage study tests a new drug called AC676 in about 60 adults with B-cell blood cancers (like certain leukemias and lymphomas) that have returned or not improved after at least two prior treatments. The main goals are to find a safe dose and check for side effects. Rese…
Phase: PHASE1 • Sponsor: Accutar Biotechnology Inc • Aim: Disease control
Last updated May 06, 2026 16:13 UTC